Status
Conditions
Treatments
About
The study will include all newborns in Normandie region for 3 years (about 105,000 births) for whom signed consent by one (or two) parents will be collected. Based on our previous pilot study (2011) assessing MCAD and PKU using tandem mass spectrometry-based method in Normandie region in which informed consents have been signed for all newborns (43,000) but we are expecting a great willingness to participate to this project. Thus, we are aiming to include 100,000 newborns, and the study will be continued until we reach at least this target.
The primary objective is to evaluate the epidemiology of MPS1 and Pompe disease using dried blood samples in the first cohort of neonates tested in France (Normandie region).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
There are no criteria for non-inclusion in this study. Participation in the study, such as participation in the National Neonatal Screening Program, is not mandatory.
Primary purpose
Allocation
Interventional model
Masking
100,000 participants in 1 patient group
Loading...
Central trial contact
Julien BLOT; Soumeya BEKRI, Pr
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal